A practical reference on thymosin alpha 1: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-19. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Alexios' concentration of power in the hands of his Komnenos dynasty meant the most serious political threats came from within the imperial family—before his coronation, John II had to overcome his mother Irene and his sister Anna, and the primary threat during his reign was his brother Isaac. John campaigned annually and extensively—he fought the Pechenegs in 1122, the Hungarians in the late 1120s, and the Seljuks throughout his reign, waging large campaigns in Syria in his final years—but he did not achieve large territorial gains. In 1138, John raised the imperial standard over the Crusader Principality of Antioch to intimidate the city into allying with the Byzantines, but did not attack, fearing that it would provoke western Christendom to respond. Manuel I used the considerable financial resources left by his father in pursuit of his ambitions, and also to secure the empire's position in an increasingly multilateral geopolitical landscape. Through a combination of diplomacy and subsidies, he cultivated a network of allies and client rulers around the empire: the Turks of the Sultanate of Rum, the Kingdom of Hungary, the Cilician Armenians, Balkan princes, Italian and Dalmatian cities, and most importantly Antioch and the Crusader States, marrying one of their princesses in 1161. Manuel managed the difficult passage of the Second Crusade through Byzantine territories in 1147, but the campaign's failure was blamed on the Byzantines by western contemporaries.
== Notes == a "Points" refers to carry-over points accrued following the sanction. For example, 154.69 points draw a one-match suspension, with 54.69 carry-over points (for every 100 points, a one-match suspension is given). f Son of Anthony Daniher (118 Games). r Restricted Free agent s Denotes amount of seasons on the Essendon list only. H Home game. A Away game. b Relegated to 9th place due to AFL Sanctions
=== Synthesis === The chemical synthesis of LSD has been described. It is commonly synthesized by reacting diethylamine with an activated form of lysergic acid. Activating reagents include phosphoryl chloride and peptide coupling reagents. Lysergic acid is made by alkaline hydrolysis of lysergamides like ergotamine, a substance usually derived from the ergot fungus on agar plate. Lysergic acid can also be produced synthetically, although these processes are not used in clandestine manufacture due to their low yields and high complexity. Albert Hofmann synthesized LSD in the following manner: (1) hydrazinolysis of ergotamine into D- and L-isolysergic acid hydrazide, (2) separation of the enantiomers with di-(p-toluyl)-D-tartaric acid to get D-isolysergic acid hydrazide, (3) enantiomerization into D-lysergic acid hydrazide, (4) substitution with HNO2 to D-lysergic acid azide and (5) finally substitution with diethylamine to form D-lysergic acid diethylamide. The precursor for LSD, lysergic acid, has been produced by GMO baker's yeast.
=== Binary, anionic === Group 3 elements scandium and yttrium, as well as lanthanum, form the 20-electron monoanions [Sc(CO)8]−, [Y(CO)8]−, and [La(CO)8]−. Group 4 elements as dianions resemble neutral group 6 derivatives: [Ti(CO)6]2−. Group 5 elements as monoanions resemble again neutral group 6 derivatives: [V(CO)6]−. Group 6 elements form (inter alia) anions with the lowest known oxidation state for transition metals: Cr(CO)4−3, Mo(CO)4−3, and W(CO)4−3. Group 7 elements as monoanions resemble neutral group 8 derivatives: [Mn(CO)5]−, [Tc(CO)5]−, [Re(CO)5]−. Group 8 elements as dianaions resemble neutral group 10 derivatives: [Fe(CO)4]2−, [Ru(CO)4]2−, [Os(CO)4]2−. Condensed derivatives are also known. Group 9 elements as monoanions resemble neutral group 10 metal carbonyl. [Co(CO)4]− is the best studied member. Large anionic clusters of nickel, palladium, and platinum are also well known. Many metal carbonyl anions can be protonated to give metal carbonyl hydrides.
Sources: en.wikipedia.org
== Discovery == Aerographene was discovered in 2013 at Zhejiang University by a team of scientists led by Gao Chao. He and his team had already successfully created macroscopic materials made out of graphene. These materials were one-dimensional and two-dimensional. However, when synthesizing aerographene, the scientists instead created a three-dimensional structure. The synthesis was accomplished by the freeze-drying of carbon nanotube solutions and large amounts of graphene oxide. Residual oxygen was then removed chemically.
The degree of strictness of border controls varies across countries and borders. In some countries, controls may be targeted at the traveller's religion, ethnicity, nationality, or countries visited. Others may need to ensure the traveller has paid the appropriate fees for their visas and has future travel planned outside the country. Yet others may concentrate on the contents of the traveller's baggage and imported goods to ensure nothing is being carried that might pose a biosecurity risk to the country.
phosphate backbone Also phosphodiester backbone, sugar–phosphate backbone, and phosphate–sugar backbone. The linear chain of alternating phosphate and sugar compounds that results from the linking of consecutive nucleotides in the same strand of a nucleic acid molecule, and which serves as the structural framework of the nucleic acid. Each individual strand is held together by a repeating series of phosphodiester bonds connecting each phosphate group to the ribose or deoxyribose sugars of two adjacent nucleotides. These bonds are created by ligases and broken by nucleases.
=== Importance of resistivity === In an imperfectly conducting fluid, the magnetic field can generally move through the fluid according to a diffusion law, with the resistivity of the plasma serving as a diffusion constant. This means that solutions to the ideal MHD equations are applicable only for a limited time within a region of a given size before diffusion becomes too significant to ignore. One can estimate the diffusion time across a solar active region (from collisional resistivity) to be hundreds to thousands of years, much longer than the actual lifetime of a sunspot, so it would seem reasonable to ignore the resistivity. By contrast, a meter-sized volume of seawater has a magnetic diffusion time measured in milliseconds. Even in physical systems that are large and conductive enough that simple estimates of the Lundquist number suggest that the resistivity can be ignored, resistivity may still be important: many instabilities can increase the effective resistivity of the plasma by factors greater than 109. The enhanced resistivity is usually the result of the formation of small-scale structures such as current sheets or fine-scale magnetic turbulence, introducing small spatial scales into the system over which ideal MHD breaks down and magnetic diffusion can occur rapidly. When this happens, magnetic reconnection may occur in the plasma, releasing stored magnetic energy as waves, bulk mechanical acceleration of material, particle acceleration, and heat.
The coexistence of various non-enzymatically replicating sequences could help to maintain a sufficient diversity of RNA modules used later to build molecules with catalytic functions. From the mathematical point of view, it is possible to find conditions required for cooperation of several hypercycles. However, in reality, the cooperation of hypercycles would be extremely difficult, because it requires the existence of a complicated multi-step biochemical mechanism or an incorporation of more than two types of molecules. Both conditions seem very improbable; therefore, the existence of coupled hypercycles is assumed impossible in practice. Evolution of a hypercycle ensues from the creation of new components by the mutation of its internal species. Mutations can be incorporated into the hypercycle, enlarging it if, and only if, two requirements are satisfied. First, a new information carrier Inew created by the mutation must be better recognized by one of the hypercycle's members Ii than the chain Ii+1 that was previously recognized by it. Secondly, the new member Inew of the cycle has to better catalyse the formation of the polynucleotide Ii+1 that was previously catalysed by the product of its predecessor Ii. In theory, it is possible to incorporate into the hypercycle mutations that do not satisfy the second condition. They would form parasitic branches that use the system for their own replication but do not contribute to the system as a whole.
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.